about
Photoinduced intercalation and coordination of a dirhodium complex to DNA: dual DNA binding.Comparison of Intracellular Stress Response of NCI-H526 Small Cell Lung Cancer (SCLC) Cells to Platinum(II) Cisplatin and Platinum(IV) Oxoplatin.Different apoptotic effects of [Pt(O,O'-acac)(γ-acac)(DMS)] and cisplatin on normal and cancerous human epithelial breast cells in primary cultureTitanocene-phosphine derivatives as precursors to cytotoxic heterometallic TiAu2 and TiM (M = Pd, Pt) compounds. Studies of their interactions with DNAOrganometallic Palladium Complexes with a Water-Soluble Iminophosphorane Ligand as Potential Anticancer Agents.Identifying therapeutic targets in gastric cancer: the current status and future directionEffects of solvents on in vitro potencies of platinum compoundsCombination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancerComparison of the effects of the oral anticancer platinum(IV) complexes oxoplatin and metabolite cis-diammine-tetrachlorido-platinum(IV) on global gene expression of NCI-H526 cellsHeterometallic titanium-gold complexes inhibit renal cancer cells in vitro and in vivo.Organic Anion Transporting Polypeptide 5A1 (OATP5A1) in Small Cell Lung Cancer (SCLC) Cells: Possible Involvement in Chemoresistance to Satraplatin.Pharmacological modulation of cytotoxicity and cellular uptake of anti-cancer drugs by PDE5 inhibitors in lung cancer cellsCommon Chemical Inductors of Replication Stress: Focus on Cell-Based Studies.Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs.Picoplatin pharmacokinetics and chemotherapy of non-small cell lung cancer.Metallomics insights into the programmed cell death induced by metal-based anticancer compounds.Liposomal delivery and polyethylene glycol-liposomal oxaliplatin for the treatment of colorectal cancer (Review).MicroRNA-218 promotes cisplatin resistance in oral cancer via the PPP2R5A/Wnt signaling pathway.Platinum complexes as light promoted anticancer agents: a redefined strategy for controlled activation.Unsymmetric mono- and dinuclear platinum(IV) complexes featuring an ethylene glycol moiety: synthesis, characterization, and biological activity.5-Nitro-2-(3-phenylpropylamino) benzoic acid induced drug resistance to cisplatin in human erythroleukemia cell lines.In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines.Overexpression of CYP3A4 in a COLO 205 Colon Cancer Stem Cell Model in vitro.In vitro cytotoxicity of combinations of dichloroacetate with anticancer platinum compounds.Combination of palladium nanoparticles and tubastatin-A potentiates apoptosis in human breast cancer cells: a novel therapeutic approach for cancer.Platinum-Based Drugs and DNA Interactions Studied by Single-Molecule and Bulk Measurements.Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effectsOxaliplatin reacts with DMSO only in the presence of water.Novel mitochondria targeted copper(ii) complexes of ferrocenyl terpyridine and anticancer active 8-hydroxyquinolines showing remarkable cytotoxicity, DNA and protein binding affinity.Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.The Ethnopharmacological and Nutraceutical Relevance of (Willd.) Amin ex C. JeffreyPlatinum and Palladium Polyamine Complexes as Anticancer Agents: The Structural FactorKinetics and mechanistic investigation into the possible activation of imidazolium trans-[tetrachloridodimethylsulfoxideimidazoleruthenate(iii)], NAMI-A, by 2-mercaptoethane sulfonate
P2860
Q30806098-73EB35FC-DB84-4ACC-8FC5-E348952D1A86Q34309915-E74C26AE-8150-41A8-B65D-F0AC3C3003F1Q34619471-D60A37DF-34E4-4A53-9517-6E74ED0909F8Q35489393-0CB62738-3E7B-4D91-947F-C750C0A1D02FQ36304307-A661797B-725A-44D7-80F1-BF6E3A36F5F1Q36398732-A7C08BD6-7A78-4AAB-8F23-45F27A75824AQ36429953-26440A7B-C66B-4DA2-92DF-C42E3E944454Q36537920-A154AEEF-BA93-4509-AE9A-5174070C5DC7Q36890460-025820E1-E009-400D-9A37-AC0AF1211F0DQ36908264-FC3BBC22-33D5-422A-99F6-4F875D4F15EEQ37218907-A8055E4F-2B82-4D68-B6C3-2AD704B20CCBQ37395863-C55DB163-7B08-4223-966B-923B70428485Q37729428-21114EFC-E1B5-47AD-A442-38903E35D3DDQ38011996-E155A75F-C0C3-42D5-9D87-4D24888219A3Q38119531-673C37EC-8AE3-4A09-A252-9124B9138BBBQ38199383-8A13EFA3-F00C-4F48-BA11-F4AFEEC0BA74Q38205769-75D126A7-5BD4-48C6-9197-8C425F58B7AFQ38604500-A4AFA854-8225-4AED-AA4A-0CFC9FE0B50DQ38791247-6F26E4E6-F125-4A1C-B321-641E2FD6FB29Q39235908-70C5DA1F-2CF1-4DA0-AC43-5B24EF8B6092Q39549097-DF95B91D-57C5-44D9-9A6F-3AE77B7AAF66Q39607350-5DC48628-9375-47B5-93AE-582D0D5DCF26Q39614141-425BE539-B404-4095-BD02-32319B594AE8Q40541533-948F53E7-28E8-4697-A4F2-796921E46F38Q41382946-D647E00B-7028-4CC4-B3D1-02DA7F8FE98FQ41974039-E6F27E50-B376-4819-AE59-8B6C5EA5DF7FQ42575787-E51FFAAC-816A-4BE7-9C5C-B36F2B4284F1Q46343946-92A3E1BA-30AC-4119-8704-AD19D4837358Q46449120-5AF0C8B8-1D46-4786-88F1-748C3C6F4655Q47309064-25A640FB-6E34-49DE-B95A-14CFA2E1CF5FQ56357205-F16294FC-AAD4-48C5-9310-313D5CC355D9Q58993871-79700220-F6E8-43F6-A283-2F2FBE476483Q59205403-459E7983-00D6-4EDD-A0E7-2B4AACB47777
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A better platinum-based anticancer drug yet to come?
@en
A better platinum-based anticancer drug yet to come?
@nl
type
label
A better platinum-based anticancer drug yet to come?
@en
A better platinum-based anticancer drug yet to come?
@nl
prefLabel
A better platinum-based anticancer drug yet to come?
@en
A better platinum-based anticancer drug yet to come?
@nl
P1476
A better platinum-based anticancer drug yet to come?
@en
P2093
Gerhard Hamilton
Ulrike Olszewski
P304
P356
10.2174/187152010791162306
P577
2010-05-01T00:00:00Z